🚀 VC round data is live in beta, check it out!
Guilin Sanjin Valuation Multiples
Discover revenue and EBITDA valuation multiples for Guilin Sanjin and similar public comparables like Zhejiang Ausun, Pharming, Youcare Pharmaceutical, GuangYuYuan Chinese and more.
Guilin Sanjin Overview
About Guilin Sanjin
Guilin Sanjin Pharmaceutical Co Ltd is engaged in research and development of proprietary Chinese medicines and natural medicines.
Founded
2001
HQ
Employees
752
Website
Sectors
Financials (FY)
EV
$1B
Guilin Sanjin Financials
Guilin Sanjin reported last fiscal year revenue of $321M and EBITDA of $112M.
In the same fiscal year, Guilin Sanjin generated $236M in gross profit, $112M in EBITDA, and $76M in net income.
Guilin Sanjin P&L
In the most recent fiscal year, Guilin Sanjin reported revenue of $321M and EBITDA of $112M.
Guilin Sanjin expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $321M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $236M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 73% | XXX | XXX | XXX |
| EBITDA | — | XXX | $112M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 26% | XXX | XXX | XXX |
| Net Profit | — | XXX | $76M | XXX | XXX | XXX |
| Net Margin | — | XXX | 24% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Guilin Sanjin Stock Performance
Guilin Sanjin has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Guilin Sanjin's stock price is $2.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -1.3% | XXX | XXX | XXX | $0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGuilin Sanjin Valuation Multiples
Guilin Sanjin trades at 3.3x EV/Revenue multiple, and 9.4x EV/EBITDA.
Guilin Sanjin Financial Valuation Multiples
As of April 11, 2026, Guilin Sanjin has market cap of $1B and EV of $1B.
Equity research analysts estimate Guilin Sanjin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guilin Sanjin has a P/E ratio of 16.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 12.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.5x | XXX | XXX | XXX |
| P/E | — | XXX | 16.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 14.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Guilin Sanjin Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Guilin Sanjin Margins & Growth Rates
Guilin Sanjin's revenue in the last fiscal year grew by 1%.
Guilin Sanjin's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Guilin Sanjin Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Guilin Sanjin Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zhejiang Ausun | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Youcare Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| GuangYuYuan Chinese | XXX | XXX | XXX | XXX | XXX | XXX |
| ArriVent BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guilin Sanjin M&A Activity
Guilin Sanjin acquired XXX companies to date.
Last acquisition by Guilin Sanjin was on XXXXXXXX, XXXXX. Guilin Sanjin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Guilin Sanjin
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGuilin Sanjin Investment Activity
Guilin Sanjin invested in XXX companies to date.
Guilin Sanjin made its latest investment on XXXXXXXX, XXXXX. Guilin Sanjin invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Guilin Sanjin
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Guilin Sanjin
| When was Guilin Sanjin founded? | Guilin Sanjin was founded in 2001. |
| Where is Guilin Sanjin headquartered? | Guilin Sanjin is headquartered in China. |
| How many employees does Guilin Sanjin have? | As of today, Guilin Sanjin has over 752 employees. |
| Is Guilin Sanjin publicly listed? | Yes, Guilin Sanjin is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Guilin Sanjin? | Guilin Sanjin trades under 002275 ticker. |
| When did Guilin Sanjin go public? | Guilin Sanjin went public in 2009. |
| Who are competitors of Guilin Sanjin? | Guilin Sanjin main competitors are Zhejiang Ausun, Pharming, Youcare Pharmaceutical, GuangYuYuan Chinese. |
| What is the current market cap of Guilin Sanjin? | Guilin Sanjin's current market cap is $1B. |
| What is the current revenue of Guilin Sanjin? | Guilin Sanjin's last fiscal year revenue is $321M. |
| What is the current EV/Revenue multiple of Guilin Sanjin? | Current revenue multiple of Guilin Sanjin is 3.3x. |
| Is Guilin Sanjin profitable? | No, Guilin Sanjin is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.